Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience.
Bas VaarwerkCoralie MallebrancheMaria C AffinitaJohanna H van der LeeAndrea FerrariJulia C ChisholmAnne-Sophie DefachellesGian Luca De SalvoNadège CorradiniVeronique Minard ColinCarlo MorosiHervé J BrisseKieran McHughGianni BisognoRick Robert van RijnDaniel OrbachJohannes Hendrikus Maria MerksPublished in: Cancer (2019)
Although systematic routine imaging is the standard of care after RMS therapy, the majority of relapses were detected as a result of clinical symptoms. This study found no survival advantage for patients whose relapse was detected before the emergence of clinical symptoms. These results show that the value of off-therapy surveillance is controversial, particularly because repeated imaging may also entail potential harm.
Keyphrases
- high resolution
- public health
- newly diagnosed
- end stage renal disease
- healthcare
- ejection fraction
- palliative care
- chronic kidney disease
- prognostic factors
- mass spectrometry
- bone marrow
- depressive symptoms
- chronic pain
- fluorescence imaging
- mesenchymal stem cells
- risk assessment
- health insurance
- human health
- pain management
- patient reported
- affordable care act